BioAlliance Pharma (BIO)

Business description

BioAlliance Pharma is a French drug development company focused on orphan cancer and supportive care treatments. It has two FDA-approved specialty products and three clinical-stage orphan oncology candidates.

Share price chart

Share chart

Stock data

Market cap.US$162m
Last closeUS$7.830
High / Low (52 weeks)US$10.5 / US$3.4
Stock market listingEuronext Paris
Forecast net cash (€m)10.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(13.2)42.486.0
Relative *(15.8)36.949.6

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Acorda Therapeutics
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarin AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Arena Pharmaceuticals
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Avita Medical Basilea
Bavarian Nordic Bellus Health
Benitec Biopharma BioCryst Pharmaceuticals
BioInvent BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron BTG
Can-Fite BioPharma Cardio3 BioSciences
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imperial Innovations Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MolMed Mologen AG
MorphoSys Nanobiotix
Nanosonics Nektar Therapeutics
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Omega Diagnostics Group
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onyx Pharmaceuticals
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
OvaScience Oxford BioMedica
Paion Paladin Labs
Patheon Pharmacyclics
Pharmaxis Pharming Group
Photocure Phylogica
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Regeneus
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
Stem Cell Therapeutics StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Topotarget
Transgene Trimel Pharmaceuticals
UCB United Drug
Vectura Verastem
Verisante Inc Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Zealand Pharma
Zeltia Ziopharm Oncology
Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2011A 3.2 (15.3) (14.6) (83.00) N/A N/A
2012A 4.0 (12.1) (11.5) (65.00) N/A N/A
2013E 3.8 (13.1) (12.8) (66.42) N/A N/A
2014E 6.3 (10.7) (10.4) (50.48) N/A N/A

Last updated on 27/03/2014

Investment summary

2014 will be a critical year for BioAlliance, with key proof-of-concept data from the large ongoing Phase II trial for oral mucositis product Validive by end 2014. Furthermore, additional planned safety assessments will help to further de-risk Livatig, currently in Phase III development for liver cancer with headline data expected in H116. Sitavig (cold sores) was recently partnered in the US in exchange for $5m in upfront and milestone payments in addition to double-digit royalties; US launch is expected in Q314.

Last updated on 31/03/2014

Industry outlook

BioAlliance develops drugs for orphan oncology indications and to treat infection. Most of its products are widely used medicines in new formulations for novel indications, which either address significant unmet medical needs or have a clear point of differentiation over current treatments. The former are the more valuable, but the latter still have considerable commercial potential.

Last updated on 31/03/2014

Key management

Judith Greciet, CEO
Nicolas Fellmann, CFO
Pierre Attali, COO

Company address

49 Boulevard du Général Matrial Valin
Paris
75015
France
+33 (0)1 45 58 71 00
View website